Optimal dose of adrenaline auto-injector for children and young people at risk of anaphylaxis: A phase IV randomized controlled crossover study. (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/all.15675
PubMed Identifier: 36794963
Publication URI: http://europepmc.org/abstract/MED/36794963
Type: Journal Article/Review
Volume: 78
Parent Publication: Allergy
Issue: 7
ISSN: 0105-4538